At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 138 enrolled
Drug / intervention
Lupin's Pegfilgrastim +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Comparative, Parallel Group Study to Assess the Immunogenicity of Lupin's Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer
In Brief
A Phase 4 clinical trial evaluating Lupin's Pegfilgrastim and Neulasta® for Breast Cancer. Completed, enrolled 138 participants across 17 sites.
Detailed Summary
The purpose of this study is to compare the immunogenicity of Peg-filgrastim versus Neulasta® as an adjunct to chemotherapy in patients with breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionJan 2019
TodayJul 2026
First PostedApr 27, 2018
Enrollment StartMar 6, 2018
Primary CompletionJan 9, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.2 years ago
Interventions
Lupin's Pegfilgrastimdrug
Administration of Pegfilgrastim
Neulasta®drug
Administration of Neulasta®